
Nemo focuses
Articles
-
1 week ago |
ark-invest.com | Nemo focuses |Nemo Marjanovic |Brett Winton
In this episode of FYI – For Your Innovation, Brett Winton and ARK analyst Nemo Despot sit down with Generate Biomedicines CEO Mike Nally and CFO Jason Silvers to explore how generative AI is transforming the discovery and development of protein-based therapeutics.
-
3 weeks ago |
ark-invest.com | Nemo focuses |Nemo Marjanovic |Brett Winton
In this episode of FYI - For Your Innovation, ARK’s Chief Futurist, Brett Winton, and Research Analyst Nemo Marjanovic, sit down with Dr. Jin Hyung Lee, a leading neuroscience researcher at Stanford University. Dr. Lee and her team are pioneering breakthroughs in understanding brain function—an essential step toward diagnosing and treating neurological disorders.
-
2 months ago |
ark-invest.com | Nemo focuses |Brett Winton |Nemo Marjanovic |Tasha Keeney
Apple has delayed the release of some of its most widely touted Apple Intelligence features until 2026 or later.1 Though the delay may be a surprise to seasoned Apple observers,2 disruptive technologies are challenging for incumbents—now including Apple—to incorporate.3 The characteristics that make AI interesting may not be consistent with Apple’s buttoned-up, optimized ecosystem.
-
Jan 24, 2025 |
ark-invest.com | Nemo focuses |Nemo Marjanovic |Brett Winton
In this episode of FYI, Brett Winton and Nemo Marjanovic sit down with Professor Thomas Hartung, MD-PhD, a leading expert in biomedical innovation at Johns Hopkins Bloomberg School of Public Health. They explore how human organoids—3D organ proxies—are revolutionizing drug discovery and toxicology testing by reducing reliance on animal models.
-
Jan 21, 2025 |
ark-invest.com | Nemo focuses |Daniel C. Maguire |Brett Winton |Nemo Marjanovic
Biotech investors are witnessing a growing divergence between private and public markets, both in valuations and performance. Private investors are betting on long-term innovation, while public markets are focusing on short-term profitability. Will regulatory and economic shifts close that gap? In 2024, the private market in biotech bounced back with 96 megarounds (nine-figure financing) that approached the 106 funded in 2021.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →